Business Context and Reporting Period
This Form 8-K Current Report is filed by CareDx, Inc. (CDNA) for the reporting period ending June 30, 2021. The filing primarily addresses corporate governance changes, specifically the appointment of a new director to the Board of Directors.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on the appointment of a director and associated compensation arrangements.
Material Changes
The material change reported is the appointment of Hannah A. Valantine, M.D., as a Class I director, effective July 1, 2021. Dr. Valantine is a Professor of Medicine at Stanford University School of Medicine and a co-inventor of the donor-derived cell-free DNA technology licensed by CareDx for the diagnosis of transplant rejection.
Guidance, Outlook, and Compensation Details
The filing details the compensatory arrangements for Dr. Valantine as a non-employee director:
- Annual Cash Retainer: $40,000, paid quarterly (electable as cash or stock).
- Initial Stock Option: Grant date fair value of $150,000, vesting monthly over three years.
- Initial Restricted Stock Units (RSUs): Grant date fair value of $150,000, vesting in three equal annual installments.
- Annual Automatic Grants: Upon each annual stockholder meeting, an option with a fair value of $100,000 and RSUs with a fair value of $100,000 will be automatically granted.
The Company also entered into a standard indemnification agreement with Dr. Valantine. No guidance, outlook, or risk factors regarding financial performance are provided in this specific filing.
Investor Verification Checklist
- Verify the commencement date of Dr. Valantine's service (July 1, 2021) and her Class I director status.
- Confirm the total grant date fair value of initial equity awards ($300,000 combined for options and RSUs).
- Review the vesting schedules for the initial grants (monthly for options, annual for RSUs) and the automatic annual grants.
- Check for any potential conflicts of interest given Dr. Valantine's role as a co-inventor of the Company's core technology and her concurrent board service at Pacific Biosciences.